Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Single-blind, Active- and Vehicle-controlled Study to Assess the Safety, Tolerability, and Efficacy of 2.4% Terbinafine Hydrochloride Topical Solution (AP4500) in Participants With Mild to Moderate Onychomycosis of the Toenails

NCT07382427 is registered in ClinicalTrials.gov with Onyx Axiom as lead sponsor.

NCT NCT07382427
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07382427 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Single-blind, Active- and Vehicle-controlled Study to Assess the Safety, Tolerability, and Efficacy of 2.4% Terbinafine Hydrochloride Topical Solution (AP4500) in Participants With Mild to Moderate Onychomycosis of the Toenails
Lead sponsor
Onyx Axiom
Phase
Phase 2
Overall status
Not yet recruiting
Start date
March 31, 2026
Completion date
February 29, 2028
Enrollment
200 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

onychomycosis of toenail